PCC1

TL;DR

Senescent cell clearance is a core longevity mechanism — directly measurable as SASP biomarker reduction (IL-6, CRP) in blood panels
PCC1’s selective senolytic action (spares healthy cells) means the wearable signal should reflect clearance benefits, not acute toxicity
The pulse-then-regenerate cycle (senolytic → NAD support) maps to a practical two-phase protocol Vitals could recommend
Stacking with Retatrutide addresses both existing senescent cell burden (PCC1) and prevention of new ones (GLP-1/GCGR metabolic optimization)


Status	Research-only; NCT06641869 human trial completed (cosmetic/skin endpoint)
Class	Trimeric procyanidin B-type / natural senolytic / senomorphic at low dose
Core mechanism	Mitochondrial outer membrane permeabilization (MOMP) in senescent cells → ROS burst → NOXA/PUMA upregulation → apoptosis; healthy cells spared
Key animal result	9.4% lifespan extension, late-life intervention (24–27 months); 65% hazard reduction
Dosing	~97 mg human estimate (60 kg); requires enriched or liposomal delivery
Main risk	Oral bioavailability requires formulation; plain GSE is insufficient
Evidence level	Strong preclinical (Nature Metabolism 2021); human trial done but cosmetic endpoint only

Dose	Effect	Mechanism
Low (1–20 μM)	Senomorphic	SASP suppression — reduces inflammation without killing cells
High (50 μM+)	Senolytic	MOMP → mitochondrial collapse → apoptosis in senescent cells only

Localizes to senescent cell mitochondria (senescent mitochondria are selectively vulnerable)
Induces MOMP (mitochondrial outer membrane permeabilization)
ROS burst inside the senescent cell
Upregulates NOXA and PUMA (pro-apoptotic BCL-2 family)
Downregulates BCL-2 and BCL-XL (anti-apoptotic)
Healthy cells are spared — robust mitochondria and higher ROS tolerance provide protection

Agent	Mechanism	Key Problem
Dasatinib + Quercetin	Multi-kinase inhibition	PAH, effusions, cytopenias
Navitoclax	BCL-2 family inhibition	Thrombocytopenia — platelet death
Fisetin	PI3K/AKT inhibition	Less potent than PCC1
FOXO4-DRI	p53 disruption	Peptide = poor oral bioavailability
PCC1	MOMP/ROS	Formulation required

Lifespan (mice, Nature Metabolism 2021): 9.4% extension with late-life biweekly IP injection (20 mg/kg); 65% hazard reduction; compression of morbidity
Human trial (NCT06641869, 2024): 74 females 45–65, 12 weeks PCC1 + pterostilbene + spermidine — skin barrier function, wrinkle reduction, texture improvement
Tissue clearance: Significant SA-β-gal reduction in liver, lungs, kidneys, prostate (mouse)
2024–2025 expanded: Retinal aging (electrophysiological restoration); hematopoietic/immune rejuvenation (Nedd4 upregulation, CD62L-Ca²⁺ axis); vascular aging (aortic PWV, endothelial function)
Formulation is the variable: High tissue accumulation (adipose, lymphoid) compensates for low plasma nmol levels; enriched extracts and liposomal delivery are the viable paths
Confidence level: High for animal senolytic mechanism and lifespan; moderate for human translation (cosmetic endpoint trial only)

Risk	Detail
Oral bioavailability	Low plasma levels — tissue accumulation and formulation quality are the variables
Formulation required	Plain GSE insufficient (~30–80 capsules equivalent); enriched or liposomal required
Human dose validation	97 mg estimate is allometric — not empirically validated in human trials
Continuous use	Not supported by evidence; pulsed use with regeneration phase is the recommended approach
Theoretical tumor risk	Preclinical data actually shows anti-tumorigenic effect — not a practical concern
Confidence level	High preclinical; moderate human (dose, long-term safety not established)

Partner	Rationale
Retatrutide	PCC1 clears existing senescent cells; Retatrutide prevents new ones (GLP-1/GCGR metabolic optimization) — comprehensive senotherapeutic strategy
GHK-Cu	PCC1 clears; GHK-Cu rebuilds — replace cleared cells with organized ECM
Glutathione	Buffers ROS/SASP burst during senolytic clearance — protects bystander cells
NMN NAD+	Critical: senescent cells overexpress CD38 → NAD+ depletion; PCC1 clears CD38+ senescent cells → NMN becomes more effective post-clearance
QL1005	Both senolytics with different mechanisms — potentially complementary
Rapamycin	mTOR inhibition suppresses SASP; PCC1 clears cells that have already become senescent — preventative + corrective

Phase	Approach
Senolytic pulse	Enriched PCC1 extract or liposomal — periodic (frequency TBD based on SA-β-gal metrics)
Post-clearance	NAD support phase (NMN or NR) — restore NAD+ now that CD38+ senescent cells are cleared
Continuous use	Not recommended — evidence supports pulsed approach